Jefferies Financial Group Analysts Cut Earnings Estimates for HUTCHMED (China) Limited (NASDAQ:HCM)

HUTCHMED (China) Limited (NASDAQ:HCMGet Rating) – Research analysts at Jefferies Financial Group lowered their FY2022 EPS estimates for HUTCHMED in a research report issued to clients and investors on Monday, August 1st. Jefferies Financial Group analyst K. Shi now forecasts that the company will post earnings per share of ($1.97) for the year, down from their previous estimate of ($0.68). The consensus estimate for HUTCHMED’s current full-year earnings is ($2.00) per share. Jefferies Financial Group also issued estimates for HUTCHMED’s FY2023 earnings at ($1.35) EPS, FY2024 earnings at ($0.55) EPS, FY2025 earnings at $0.44 EPS and FY2026 earnings at $1.56 EPS.

Several other research firms have also weighed in on HCM. StockNews.com upgraded shares of HUTCHMED from a “sell” rating to a “hold” rating in a report on Monday, August 1st. The Goldman Sachs Group cut their target price on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of HUTCHMED from a “buy” rating to a “hold” rating in a report on Wednesday, May 4th.

HUTCHMED Trading Up 4.5 %

HCM opened at $13.88 on Thursday. The firm’s fifty day moving average is $12.14 and its two-hundred day moving average is $16.92. HUTCHMED has a twelve month low of $8.40 and a twelve month high of $43.18.

Institutional Investors Weigh In On HUTCHMED

Several large investors have recently made changes to their positions in HCM. Bellevue Group AG increased its position in shares of HUTCHMED by 62.6% during the first quarter. Bellevue Group AG now owns 1,750,690 shares of the company’s stock worth $33,123,000 after acquiring an additional 673,820 shares in the last quarter. Assenagon Asset Management S.A. grew its position in HUTCHMED by 417.8% in the second quarter. Assenagon Asset Management S.A. now owns 638,446 shares of the company’s stock valued at $8,070,000 after purchasing an additional 515,158 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in HUTCHMED in the fourth quarter valued at $12,438,000. Capital Group International Inc. CA grew its position in HUTCHMED by 4.0% in the first quarter. Capital Group International Inc. CA now owns 4,191,161 shares of the company’s stock valued at $79,297,000 after purchasing an additional 161,161 shares in the last quarter. Finally, Capital International Investors grew its position in HUTCHMED by 1.4% in the fourth quarter. Capital International Investors now owns 9,054,891 shares of the company’s stock valued at $317,923,000 after purchasing an additional 128,422 shares in the last quarter. Institutional investors own 31.03% of the company’s stock.

HUTCHMED Company Profile

(Get Rating)

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors.

Featured Articles

Earnings History and Estimates for HUTCHMED (NASDAQ:HCM)

Receive News & Ratings for HUTCHMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HUTCHMED and related companies with MarketBeat.com's FREE daily email newsletter.